Cargando…

Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda

BACKGROUND: The epidemiology of hepatitis B virus (HBV) infection in the general population in Rwanda is not well known. This study examined the prevalence of HBV surface antigen (HBsAg) positivity and associated risk factors among people aged 25 years and over in an organized national screening cam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makuza, Jean Damascene, Rwema, Jean Olivier Twahirwa, Ntihabose, Corneille Killy, Dushimiyimana, Donatha, Umutesi, Justine, Nisingizwe, Marie Paul, Serumondo, Janvier, Semakula, Muhamed, Riedel, David J., Nsanzimana, Sabin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499977/ https://www.ncbi.nlm.nih.gov/pubmed/31053097 http://dx.doi.org/10.1186/s12879-019-4013-4

Ejemplares similares

Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program
por: Makuza, Jean Damascene, et al.
Publicado: (2019)

Role of unsafe medical practices and sexual behaviours in the hepatitis B and C syndemic and HIV co-infection in Rwanda: a cross-sectional study
por: Makuza, Jean Damascene, et al.
Publicado: (2020)

Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population
por: Umutesi, Justine, et al.
Publicado: (2019)

Epidemiology of sexually transmitted infections: trends among patients screened for sexually transmitted infections in rwandan health facilities 2014–2020
por: Makuza, Jean Damascene, et al.
Publicado: (2022)

Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda
por: Umutesi, Justine, et al.
Publicado: (2017)

The Cascade of Care for Hepatitis C Treatment in Rwanda: A Retrospective Cohort Study of the 2017–2019 Mass Screening and Treatment Campaign
por: Nisingizwe, Marie Paul, et al.
Publicado: (2023)

Controlling hepatitis C in Rwanda: a framework for a national response
por: Mbituyumuremyi, Aimable, et al.
Publicado: (2018)

Impact of COVID‐19 pandemic on HCV care cascade in Rwanda: Ecological study from July 2019 to June 2021
por: Makuza, Jean Damascene, et al.
Publicado: (2022)

Prevalence and risk factors for cervical cancer and pre-cancerous lesions in Rwanda
por: Makuza, Jean Damascène, et al.
Publicado: (2015)

Maternal, obstetric and gynecological factors associated with preterm birth in Rwanda: findings from a national longitudinal study
por: Rutayisire, Erigene, et al.
Publicado: (2023)

Values and preferences for hepatitis C self-testing among the general population and healthcare workers in Rwanda
por: Serumondo, Janvier, et al.
Publicado: (2021)

Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators
por: Serumondo, Janvier, et al.
Publicado: (2020)

Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
por: Gupta, Ekta, et al.
Publicado: (2023)

Injection drug use practices and HIV infection among people who inject drugs in Kigali, Rwanda: a cross-sectional study
por: Twahirwa Rwema, Jean Olivier, et al.
Publicado: (2021)

Correction: Injection drug use practices and HIV infection among people who inject drugs in Kigali, Rwanda: a cross-sectional study
por: Rwema, Jean Olivier Twahirwa, et al.
Publicado: (2022)

Time to complete hepatitis C cascade of care among patients identified during mass screening campaigns in rural Rwanda: a retrospective cohort study
por: Kamali, Innocent, et al.
Publicado: (2022)

Spatio-temporal dynamic of the COVID-19 epidemic and the impact of imported cases in Rwanda
por: Semakula, Muhammed, et al.
Publicado: (2023)

Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients
por: Kim, Kwang Min, et al.
Publicado: (2011)

Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

What are the causes and outcomes of the coexistence of HBsAg and anti-HBs?
por: Afyon, Murat
Publicado: (2016)

Child mortality associated with maternal HIV status: a retrospective analysis in Rwanda, 2005-2015
por: Remera, Eric, et al.
Publicado: (2021)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Comparative analysis of the safety and efficacy of HBsAg-1018 versus HBsAg-Eng: a meta-analysis
por: ZHANG, LIN L., et al.
Publicado: (2020)

B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
por: Galati, Giovanni, et al.
Publicado: (2014)

Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B
por: Kwak, Min-Sun, et al.
Publicado: (2019)

Prevalence and associated risk factors for hepatitis B and C viruses among refugee populations living in Mahama, Rwanda: A cross-sectional study
por: Kamali, Innocent, et al.
Publicado: (2021)

HIV infection and engagement in HIV care cascade among men who have sex with men and transgender women in Kigali, Rwanda: a cross‐sectional study
por: Twahirwa Rwema, Jean Olivier, et al.
Publicado: (2020)

Safety and Efficacy of Limited Laboratory Monitoring for Hepatitis C Treatment: A Blinded Clinical Trial in Rwanda
por: Grant, Philip, et al.
Publicado: (2020)

Comparison of Serum HBsAg Quantitation by Four Immunoassays, and Relationships of HBsAg Level with HBV Replication and HBV Genotypes
por: Tuaillon, Edouard, et al.
Publicado: (2012)

Assessment of noninvasive liver stiffness in inactive HBsAg carriers by transient elastography: Fibroscan in inactive HBsAg carriers
por: Sporea, Ioan, et al.
Publicado: (2011)

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro
por: Salpini, Romina, et al.
Publicado: (2017)

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022)

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
por: Jiang, Shaowen, et al.
Publicado: (2023)

AUSTRALIA ANTIGEN (HBsAG) IN INSTITUTIONALISED SCHIZOPHRENICS
por: Chaudhury, S., et al.
Publicado: (1993)

HBsAg seroprevalence among Senegalese militaries
por: Ndiaye, Abdoul A, et al.
Publicado: (2015)

Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection
por: Yan, Ying, et al.
Publicado: (2022)

Accuracy Validation of the Elecsys HBsAg II Quant Assay and Its Utility in Resolving Equivocal Qualitative HBsAg Results
por: Lee, Jaehyeon, et al.
Publicado: (2023)

Experience of Rwanda on COVID-19 Case Management: From Uncertainties to the Era of Neutralizing Monoclonal Antibodies
por: Nkeshimana, Menelas, et al.
Publicado: (2022)

Workplace violence experience among nurses at a selected university teaching hospital in Rwanda
por: Musengamana, Valens, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iloam97mf6jvatdhibjn4nrus7